AMARIN CORP PLC\UK (AMRN) Form 8-K — Oct 28, 2026
Amarin reported Q3 2026 net income of $0.2 million, its first profitable quarter in over two years, driven by a 44% reduction in operating expenses following its $70 million cost savings program and the Recordati partnership restructuring. Total net revenue fell 20% YoY to $39.6 million, with U.S. VASCEPA sales down 30% on generic-competition pricing pressure, though U.S. IPE market share held at 47% and licensing/royalty revenue jumped 139% to $2.7 million.
Key figures
- Eps
- 0
- Revenue
- 39600000
- Guidance
- Cash, cash equivalents & short-term investments expected ~$330M for FY 2026; U.S. volumes broadly stable for remainder of FY 2026; positive Q4 operating cash flow expected; further opex reductions in Q4.
- Net Income
- 245000
- Total Debt
- 0
- Revenue Yoy
- -20%
- Total Assets
- 634081000
- Cash Position
- 323400000
- Us ipe market share
- 47%
- Q3 2025 revenue usd m
- 49.7
- Operating expense change
- -44%
- Patent protection through
- 2039
- Us product revenue change
- -30%
- Global partner demand growth
- 55%
- Operating cash flow q3 usd m
- 9.2
- Cost savings initiative usd m
- 70
- Nine month 2025 revenue usd m
- 164.4
- Nine month 2026 revenue usd m
- 126.9
- Recordati agreement countries
- 59
- Europe in market demand growth
- 68%
- Countries commercially available
- 22
- Licensing royalty revenue change
- 139%
- Us product revenue q3 2026 usd m
- 28.5
- Licensing royalty revenue q3 usd m
- 2.7
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.